Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Obesity
Biotech
Aardvark halts obesity trials, putting entire pipeline on pause
The voluntary pause comes less than a month after Aardvark paused a phase 3 trial for a related asset due to cardiac concerns.
Darren Incorvaia
Mar 24, 2026 4:00am
Genentech drug fails rare disease study, raising obesity questions
Mar 20, 2026 2:11pm
Lilly partner sees weight loss potential in hibernating animals
Mar 19, 2026 10:00am
Structure touts 16% weight loss 'highest efficacy' for oral GLP1
Mar 16, 2026 10:02am
Novo Holdings assets shrink by 3rd as Novo Nordisk shares fall
Mar 12, 2026 7:15am
Ascletis eyes quarterly GLP-1 dosing following phase 2 readout
Mar 10, 2026 8:20am